Sessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
|
|
- Jason Boone
- 5 years ago
- Views:
Transcription
1 Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
2 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
3 Milestone of HER2/anti-HER2 Therapies in BC
4 Survival with HER2+ Metastatic Disease Tolaney S, ASCO 2018
5 What is the optimal regimen in 1 st line regimen?
6 Swain SM, et al. NEJM 2015 Pertuzumab-Trastuzumab-Docetaxel the SOC in 1 st line HER2+ MBC...in patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly increased the median overall survival to 56.5 months, an improvement of 15.7 months over survival in the control group mos 40.8 mos 15.7 mos
7 Pertuzumab-Trastuzumab-Docetaxel in a real world setting...there is some concern and debate about whether results obtained in clinical trials can be applied tout court to clinical practice. (...) The most relevant differences between our population and patients enrolled in the CLEOPATRA trial was the presence of brain metastases, the prevalence of HR positivity, visceral vs non-visceral pattern of metastasization and the prevalence of (neo)adjuvant pretreatment with HT and trastuzumab. Importantly, as shown by our survival analyses, these differences did not seem to affect efficacy. (...) Notably, mpfs was unexpectedly much greater in the RL setting than in the CLEOPATRA trial (27.8 vs 18.5 months, respectively)... De Placido S, et al. Breast 2018
8 Pertuzumab: Key Clinical Questions? What is the efficacy of pertuzumab in trastuzumab pretreated real life populations? Can pertuzumab use be delayed until second line setting? Should pertuzumab be given beyond progression? NO, but an important question to test in clinical trial(s)
9 Baselga J, et al. NEJM 2012 What is the efficacy of pertuzumab in trastuzumab-pretreated real life populations? Baseline characteristics of patients enrolled in the CLEOPATRA trial Only a minor fraction of patients enrolled in the CLEOPATRA trial were previously exposed to Trastuzumab Are the results of the trial reproducible in real practice?
10 Ricciardi GRR & Adamo V, et al. ASCO 2017 Safety and Efficacy of the combination of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-positive MBC in pretreated patients with Trastuzumab in neo/adjuvant setting: a real-life study Population 35 Median age (range) 50 (20-71) ECOG PS, median (range) 0 (0-1) Menopausal Status, n (%) Pre-menopausal 16 (45.7) Post-menopausal 19 (54.3) Surgery, n (%) Mastectomy 17 (48.6) Quadrantectomy 18 (51.4) Lymphadenectomy n (%) 27 (77.1) Sentinel Node Biopsy n (%) 7 (20) Subtypes, n (%) Luminal B 14 (40) HER2-enriched 21 (60) Metastatis sites (%) Lung 20% Lymph nodes 14.3% Liver 11.4% Median PFS 12 mos TRASTUZUMAB Neoadjuvant, n (%) 12 (34.3) Adjuvant, n (%) 28 (80) Median OS 15.2 mos Median FU 55.6 mos
11 Pertuzumab: Key Clinical Questions? What is the efficacy of pertuzumab in trastuzumab pretreated real life populations? Can pertuzumab use be delayed until second line setting? Should pertuzumab be given beyond progression? NO, but an important question to test in clinical trial(s)
12 Is there a role for Pertuzumab- Trastuzumab outside of 1 st line? Limitations: H/X not the SOC in 2 nd line Open label design No statistically-significant improvement in PFS Benefit in OS, but less than observed in the CLEOPATRA trial (HR 0.76 vs. 0.68) Urruticoechea A, et al. ASCO 2018
13 Pertuzumab: Key Clinical Questions? What is the efficacy of pertuzumab in trastuzumab pretreated real life populations? Can pertuzumab use be delayed until second line setting?e be delayed until second line setting? Should pertuzumab be given beyond progression? NO, but an important question to test in clinical trial(s)
14 What is the optimal regimen in 2 nd and other lines?
15 Overview of improvements in OS brought by anti-her2 agents in T-pretreated pts 1 Cameron D, et al. Oncologist 2010; 2 Geyer CE, et al. NEJM 2006; 3 Blackwell KL, et al. JCO 2012; 5 Verma S, et al. NEJM 2012; 6 Krop IE, et al. Lancet Oncol 2014; 7 Wildiers H, et al. SABCS T-DM1 22,7 TH3RESA [6, 7] CAPE + LAP 15,8 T-DM1 30,9 EMILIA [5] TPC 25,1 EGF [3] LAP LAP + T 9,5 14,0 Cameron D, 2011 [1, 2] CAPE + LAP 17,25 CAPE 14,
16 Verma S, et al. NEJM 2012; Die ras V, et al. Lancet Oncol 2017 T-DM1 vs. capecitabine plus lapatinib previously treated HER2-positive MBC: the EMILIA trial...t-dm1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane...
17 Questions regarding T-DM1 What is the efficacy of T-DM1 in pertuzumab pre-treated real life populations? Should T-DM1 only be used in the second line setting?
18 Fabi A, et al. Fut Oncol 2017 What is the efficacy of T-DM1 in pertuzumabpretreated real life populations? Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and clinical benefit rate was 43.3 and 71.1%, respectively. P + T: mpfs 5.0 months (95% CI: ); T only: mpfs 11.0 months (95% CI: ) Median progression-free survival was 5.0 months in patients with prior pertuzumab and 11.0 months in those without (hazard ratio: 2.02; 95% CI: ; p = 0.01). Patients treated with T-DM1 who previously received pertuzumab have poorer clinical outcomes compared with those receiving a trastuzumab-onlybased regimen in the first-line setting.
19 Questions regarding T-DM1 What is the efficacy of T-DM1 in pertuzumab pre-treated real life populations? Should T-DM1 only be used in the second line setting?
20 Perez EA, et al. JCO 2017 & ASCO 2017 Is there a role for T-DM1 in 1 st line HER2-positive MBC? T-H= T-DM1 = T-DM1 + P T-DM1 remains the SoC in 2 nd line Possible option for first line in pts unsuitable for TPH What would be the role of T- DM1 if P (APHINITY trial) will be moved in the adjuvant setting in high risk pts?
21 What is the role of lapatinib in the pertuzumab/t-dm1 era?
22 Lapatinib remains a therapeutic option for pts with HER2-positive MBC despite being previously treated with multiple anti-her2 therapies. 50% of pts obtained clinical benefit for over 6 mos with no significant toxicity Lapatinib shows a partial lack of cross-resistance with pertuzumab and T-DM1 thus further emphasizing the benefit of using beyond the 2 nd line setting 1. Of the 34 pts identified as the target cohort with prior pertuzumab and/or T-DM1 exposure, 29 were available for outcome analysis 2. In the comparison cohort (n= 536) who had received lapatinib without prior pertuzumab and/or T-DM1 exposure, 445 pts were available for outcome analysis Ba ez-vallecillo L, et al. SABCS 2016
23 Current advanced HER2-positive breast cancer treatment guidelines Pondé N, et al. Cancer Treat Rev 2018
24 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
25 Cross-talk between different signal transduction is the best studies cause of resistance pten cbl 25 Johnston S R Clin Cancer Res 2010;16:
26 Kaufman B, et al. JCO 2009, Johnston S, et al. JCO 2009; Burstein HJ, et al. JCO 2014 Single Agent HER2 Targeted Therapy Adds Modestly To Endocrine Therapy TAnDEM EGF30008 CALGB mpfs: 4.8 vs. 2.4 mos mpfs: 8.2 vs. 3.0 mos mpfs: 5.9 vs. 3.3 mos Anastrazole vs. Anastrazole + Trastuzumab Letrozole vs. Letrozole + Lapatinib Fulvestrant vs. Fulvestrant + Lapatinib
27 1 st line Trastuzumab + AI ± Pertuzumab: the PERTAIN study Rimawi M, et al. JCO 2018
28 PERTAIN efficacy results P + T significantly improved PFS compared with trastuzumab alone in all population Among patients who did not receive induction chemotherapy: mpfs was mo in the pertuzumab+ trastuzumab arm and mo in the trastuzumab arm Rimawi M, JCO 2018
29
30 ALTERNATIVE: efficacy results Study Ph. Design Population n. Arm(s) Objectives DETECT V/CHEVENDO III Randomized, open-label 1 st -3 rd line therapy HER2+/ER+ MBC 270 CHT + T + P vs. ET + T + P AEs (primary); Quality-adjusted survival, ORR, OS, PFS (secondary) Dual HER2 blockade with LAP + TRAS + AI showed superior PFS benefit versus TRAS + AI in pts with HER2-positive/HR-positive MBC.This combination offers an effective and safe chemotherapy-sparing alternative treatment regimen for this pts population Johnston SR, et al. JCO 2018
31 CDK4/6 inhibitors in HER2+ BC
32 Adapted from Branda o M, et al. Exp Rev Anticancer Ther 2018 Ongoing clinical trials with anti-her2 agents + ET+ CDK4/6 inhibitors Study Ph. Design Population n. Arm(s) Objectives PATINA II Randomized, open-label HER2+/ER+ MBC, prior anti-her2 + CHT induction therapy 496 Palbociclib + T + P + ET vs. T + P + ET PFS (primary); OS, 3-yr/5-yr OS, ORR, DOR, CBR, PROs (secondary) PATRICIA II Randomized, open-label HER2+ MBC, 2-4 prior anti-her2 therapy lines 138 ER-: T + Palbociclib ER+: T + Palbociclib ± Letrozole PFS (primary); CBR, ORR, safety (secondary) MonarcHER II Randomized, open-label HER2+/ER+ MBC, postmenopausal, 2 prior anti-her2 therapies 225 Abemaciclib + T + Fulvestrant vs. Abemaciclib + T vs. T + SoC CHT PFS (primary); OS, ORR, DOR, CBR (secondary) Legend: CHT, chemotherapy; T, Trastuzumab; P, Pertuzumab; ET, endocrine therapy.
33 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
34 pan-her inhibitors in HER2-positive MBC STUDY Phase Drug(s) Population ORR PFS OS LUX-Breast-1 [1] III Afatinib + VNB vs. VNB + H HER2+ MBC, prior trastuzumab 46.1% vs. 47.0% 5.5 mos vs. 5.6 mos 19.6 mos vs mos LUX-Breast-3 [2] II Afatinib vs. Afatinib + VNB vs. TPC HER2+ BC with progressive BMs prior Trastzumab and/or Lapatinib 0%* vs. 8%* vs. 14%* 2.74 mos vs mos vs mos mos vs mps vs mos Martin M, 2013 [3] II Neratinib vs. Lap-Cape HER2+ MBC, prior trastuzumab 29% vs. 41% 4.5 mos vs. 6.8 mos 19.7 mos vs mos Saura C, 2014 [4] I/II Neratinib + Cape HER2+ MBC, prior trastuzumab and lapatinib 64% (no prior lapatinib) 57% (prior lapatinib) 9.27 mos (no prior lapatinib) 8.26 mos (prior lapatinib) N.R. TBCRC 022 [5] II Neratinib HER2+, BMs 8%* 1.9 mos N.R. NEfERT-T [6] II Neratinib-Tax vs. H-Tax HER2+, 1 st line 74.8% vs. 77.6% 12.9 mos vs mos N.R * Intracranial ORR 1 Harbeck N, et al. Lancet Oncol 2016; 2 Cortes J, et al. Lancet Oncol 2015; 3 Martin M, et al. Eur J Cancer 2013; 4 Saura C, et al. JCO 2014; 5 Freedman RA, et al. JCO 2016; 6 Awada A, et al. JAMA Oncol 2016
35 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
36 Brain Metastases from Breast Cancer CNS tropism Limited systemic options In the RegisHER study 37% of pts with HER2+ BC had brain mts detected over the study 7% of diagnosis 30% over course of their disease Worse outcome with presence of brain mts median survival 26.3 months with vs 44.6 months without Sperduto PW, et al. J Neurooncol. 2013; Brufsky AM, et al. Clin Cancer Res 2011
37 Morikawa A, et al. Clin Breast Cancer 2018 HER2-positive Breast Cancer With Brain Metastases in the era of HER2-targeted therapy...significantly better survival from BM was noted for patients with higher performance status, fewer BM lesions, continued use of HER2- targeted therapy after BM diagnosis, and better controlled extracranial metastatic disease. Systemic Treatment anti-her2 play an important role especially in HER2+ patients: Median OS from BMs onset can now exceed 2 years.
38 Completed prospective clinical trials of TKIs in HER2+ BC with established brain metastases Study Phase n EGF [1] II previous CHT/anti-HER2 Previous WBRT yes/yes 100% Arm(s) Lapatinib Lapatinib + Capecitabine CNS ORR TTP/PFS (mos) LANDSCAPE [2] II 45 yes/no 0% Lapatinib + Capecitabine 66% 5.5 EMILIA [3] III 95* yes/yes 60% 51% T-DM1 Lapatinib + Capecitabine 6% 20% N.R OS (mos) 6.4 N.R. 91% at 6 mos Shawky et al. [4] II 21 yes/yes 76% Lapatinib + Capecitabine 33% TBCRC [5] II 37 yes/yes 65% Neratinib + Capecitabine 49% LUX-Breast 3 [6] II 121 yes/yes 65% 74% 60% Afatinib Afatinib + Vinorelbine TPC 0% 8% 14% *Subset analysis Adapted from Duchnowska R, et al. Cancer Treat Rev 2018 [1] Lin NU, et al. Clin Cancer Res 2009; [2] Bachelot T, et al. Lancet Oncol 2013; [3 ]Krop IE, et al. Ann Oncol 2015; [4] Shawsky H, et al. J Egypt Natl Cancer Inst 2014; [5] Freedman RA, et al. JCO 2016; [6] Cortes J, et al. Lancet Oncol 2015.
39 Murthy R, et al. Lancet Oncol 2018; Borges VF, et al. JAMA Oncol The triplet combination of tucatinib, capecitabine, and trastuzumab demonstrated preliminary activity in pretreated HER2-positive pts with MBC, including patients previously treated with pertuzumab, T-DM1 and lapatinib. The mpfs in pts with brain metastases of 6.7 months was encouraging when compared with other systemic therapies used in a similar patient population......the combination of tucatinib and T-DM1 demonstrated preliminary activity in pretreated pts with ERBB2/HER2- positive MBC as reflected by a mpfs of 8.2months (95%CI, months). The mpfs among pts with brain metastases was 6.7 months (95% CI, months), which is encouraging compared with other systemic therapies used to treat a similar pts population...
40 Phase II study of Tucatinib vs. Placebo in Combination with Capecitabine & Trastuzumab in HER2+ MBC
41 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
42 New combination strategies in HER2-positive MBC Pondé N, et al. Cancer Treat Rev 2018
43 Antibody-drug conjugates Tolaney S. ASCO 2018
44 Saura C, et al. ASCO 2018 SYD985: preliminary data from HER2-positive MBC expansion cohort of the phase 1 study FDA granted Fast Track Designation
45 Novel Anti-HER2 Antibodies: Margetuximab
46 Novel Anti-HER2 Antibodies: Other
47 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
48 The prevalence of somatic mutations across human cancer types Lower median rate of somatic mutations detected compared to most immune sensitive cancers Alexandrov LB, et al. Nature 2013
49 Rationale for immunotherapy in HER2- positive breast cancer HER2+ Breast Cancer are higly infiltrated with T cells Quantity is prognostic and TIL biomarker is robust surrogate Trastuzumab has know immune MOA Trastuzumab elicits antitumor immunity producing antibody-dependent cellular cytotoxicity (ADCC) Solinas C, et al. ESMO Open. 2017; Denkert C, et al. Lancet Oncol 2017; Stagg J, et al. Proc Natl Acad Sci U S A. 2011
50 Pembrolizumab + Trastuzumab in HER2- positive MBC: the phase I/II PANACEA study Loi S, et al. SABCS 2017
51 Higher stromal TILs (stils) associated with better response and disease control Loi S, et al. SABCS 2017 stils 5% as potential predictive marker
52
53
54 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
55
56 HERITAGE: EFFICACY RESULTS Rugo HS, et al. ASCO 2018
57 Outline HER2+ MBC: where are we now? Emerging approaches in triple positive MBC Role of pan-her inhibitors Emerging therapeutic strategies in pts with brain metastases Which new anti-her2 drugs are coming? Is there a role for Immunotherapy? Trastuzumab biosimilars Final Remarks
58 Final Remarks Pertuzumab and T-DM1 led to improved outcomes with favorable toxicity in 1 st and 2 nd line HER2+ MBC, respectively, and are the preferred regimens in these settings; However, some important clinical questions (Pertuzumab in T-pretreated pts? Pertuzumab outside 1 st line? T-DM1 in pertzumab-pretreated pts?) are still open. Endocrine therapy + dual-blockade HER2 therapy is associated with significant improvement in PFS and can be considered for selected triple positive pts; In 3 rd and later lines of therapy (or where pertuzumab/tdm1 are not available), the addition of a HER2-directed agent improves outcomes compared to chemotherapy alone and thus should be continued whenever possible; Several different agents are under development in HER2-positive MBC, trying to overcome mechanisms of resistance to currently approved anti-her2 agents; For HER2-disease, Immunotherapy development still lagging behind due to effective anti-her2 therapies. The use of T biosimilars may reduce cancer care costs, with similar outcomes and safety profile to originator T.
59 Grazie!
New Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationEvolving Strategies to Overcome Resistance to HER2 Targeted Agents
Evolving Strategies to Overcome Resistance to HER2 Targeted Agents Sung-Bae Kim, MD, PhD Professor, Dept of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea Advanced HER2+
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationIl trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationSystemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More informationCerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases
More informationMalattia HER-2 positiva
Novità sul trattamento del carcinoma mammario Malattia HER-2 positiva Patrizia Vici Neoadjuvant - Adjuvant - Advanced Prognostic/Predictive factors..her-2 heterogeneity.. Neoadjuvant Phase II Pre-planned
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationWhat is the Next Goal for HER2 Targeted Therapy?
What is the Next Goal for HER2 Targeted Therapy? Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: 2017 ASCO ANNUAL MEETING 2 6 June 2017 Chicago, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationI SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI. Marta Bonotto Department of Oncology, University Hospital of Udine, Italy
I SOTTOGRUPPI FENOTIPICI E I RISULTATI SINORA RAGGIUNTI Marta Bonotto Department of Oncology, University Hospital of Udine, Italy Breast Cancer Metastatic Breast Cancer (MBC) Metastatic Breast Cancer (MBC)
More informationHER2-positive Breast Cancer The clinician s perspective
HER2-positive Breast Cancer The clinician s perspective Rupert Bartsch German Breast Group and Department of Medicine 1, Clinical Division of Oncology Medical University of Vienna Declaration of potential
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationLA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationPresent and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationTranslational Breast Cancer Research Consortium (TBCRC) 022
Phase II trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2- Positive (HER2+) Breast Cancer Brain Metastases Translational Breast Cancer Research Consortium
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More information